Trials / Completed
CompletedNCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TGR-1202 | TGR-1202 Daily Oral Dose |
Timeline
- Start date
- 2013-01-07
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2013-01-14
- Last updated
- 2021-08-23
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01767766. Inclusion in this directory is not an endorsement.